Short Interest in Haemonetics Co. (NYSE:HAE) Grows By 9.8%

Haemonetics Co. (NYSE:HAE - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 2,240,000 shares, an increase of 9.8% from the March 31st total of 2,040,000 shares. Currently, 4.5% of the shares of the company are sold short. Based on an average trading volume of 476,900 shares, the short-interest ratio is presently 4.7 days.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of HAE. Carmel Capital Partners LLC acquired a new position in shares of Haemonetics during the 3rd quarter valued at $30,000. TFO Wealth Partners LLC boosted its position in shares of Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier's stock worth $51,000 after buying an additional 589 shares during the period. Group One Trading L.P. acquired a new stake in shares of Haemonetics in the third quarter valued at about $55,000. Parkside Financial Bank & Trust raised its holdings in shares of Haemonetics by 17.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier's stock valued at $90,000 after buying an additional 156 shares during the period. Finally, C M Bidwell & Associates Ltd. lifted its position in Haemonetics by 19.7% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 2,389 shares of the medical instruments supplier's stock worth $214,000 after acquiring an additional 393 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. TheStreet downgraded Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th. Barrington Research restated an "outperform" rating and set a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. Finally, StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Friday, March 22nd.

Haemonetics Trading Up 0.6 %

Shares of NYSE HAE traded up $0.55 during midday trading on Tuesday, reaching $92.05. 548,324 shares of the stock were exchanged, compared to its average volume of 454,033. The stock has a 50 day moving average price of $81.20 and a 200-day moving average price of $82.60. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $4.68 billion, a P/E ratio of 37.42, a P/E/G ratio of 2.15 and a beta of 0.36. Haemonetics has a 52-week low of $70.74 and a 52-week high of $95.26.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. During the same quarter in the prior year, the company posted $0.85 EPS. The company's quarterly revenue was up 10.1% compared to the same quarter last year. Equities research analysts expect that Haemonetics will post 3.95 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.